🔗 Share this article

While America proceeds with sweeping revisions to its vaccine guidelines, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines throughout the pandemic and has zeroed in on possible fatalities following COVID-19 immunization in her recent time at the FDA.

Planned Overhauls to Childhood Immunization Schedule

Public health authorities had intended to announce sweeping changes to the childhood immunization program earlier this month, aligning the US with Denmark’s vaccine program, according to reports – a substantial departure that would put the US out of alignment with many the international standard with no evidence for improved outcomes. This reveal has been delayed until the new year.

Rather than Vinay Prasad, Dr. Høeg is set to present at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to lead the center this year.

A Shift at the FDA

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a greater focus upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric vaccine recommendations in the US so as to align more like the Danish model, a society with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – typically the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no obvious track record in pharmaceutical research, regulation or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in managing a large organization. She has no expertise in drug approvals.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the science of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who headed CBER have had.”

CDER has an enormous range of responsibilities at the agency, Woodcock emphasized.

“Many people just focuses on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There is also a biosimilars division, non-prescription drug unit and other areas, and all of those need to be managed,” Dr. Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the position, which oversees in excess of 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” the former official concluded.

Agency Reaction and Disputed Programs

When asked about inquiries about Dr. Høeg's qualifications and whether this selection represents increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “questions stem from inaccurate premises”.

“Her resume aligns with the functions of her role,” the representative stated, citing the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's recently launched priority voucher program, a disputed expedited therapy clearance system that allegedly concerned her predecessors. “How are these drugs being picked for this fast-track system? Who is making the decisions?” Dr. Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards laxer regulations of all drugs, aside from immunizations.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a clearer, if problematic, track record, Howard have noted. She released a analysis using unverified volunteer-provided data to assess the rate of myocarditis following Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming federal leadership featured revising guidelines for recently developed shots and discontinuing “optional” vaccines, she stated post-election on a podcast. At the agency, Dr. Høeg has reportedly suggested barring adolescent males from receiving COVID-19 vaccines.

“She’s an thorough dogmatist who commences with her conclusions and tailors the evidence to retrofit the evidence in a extremely disingenuous, fraudulent fashion,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|